Gapping up
In reaction to strong earnings/guidance:
- PAHC +5.5%, DSW +4%, STAF +3.6%, ADHD +2.1%
M&A news:
- MDLZ +3.6% (no longer pursuing combination with HSY)
Select EU financial related names showing strength:
- DB +2.4%, BCS +2.0%, CS +1.8%, HSBC +1.3%, LYG +1.3%, SAN +1.0%
Other news:
- BCEI +32% (receives continued listing standard notice from the NYSE; elects to pay interest on its senior unsecured notes)
- KMDA +7.9% (meets primary endpoint of US phase 2 study of inhaled alpha-1 antitrypsin for the treatment of alpha-1 antitrypsin deficiency)
- PTLA +2.1% (reports interim results from ongoing Phase 3b/4 ANNEXXA-4 study)
- NAT +1.6% (sends letter to shareholders; CEO informs of recent stock purchases)
- CZR +0.9% (Reportedly wins two-week reprieve from bondholder lawsuits)
- CAVM +0.6% (CFO buys shares), REGN +0.5% (Positive Barron's mention)
- LUV +0.5% (Reaches agreement in principle on a new contract with its pilots)
Analyst comments:
- SPHS +4.7% (initiated with a Overweight at Piper Jaffray)
- UAL +4.6% (upgraded to Outperform from Mkt Perform at Raymond James)
- GEMP +2% (initiated with a Outperform at RBC Capital Mkts)
- FTNT +1.4% (upgraded to Overweight from Sector Weight at Pacific Crest)